<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article article-type="case-report" dtd-version="1.0" xml:lang="hr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LV</journal-id>
<journal-id journal-id-type="nlm-ta">Lijec Vjesn</journal-id>
<journal-title-group>
<journal-title>Lijecnicki Vjesnik</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Lijec. Vjesn.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">0024-3477</issn>
<issn pub-type="epub">1849-2177</issn>
<publisher><publisher-name>Croatian Medical Association</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">LV-146-35</article-id>
<article-id pub-id-type="doi">10.26800/LV-146-1-2-5</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Clinical observation</subject></subj-group>
</article-categories>
<title-group>
<article-title>Opona&#x0161;atelji klini&#x010D;ke slike nasljednog (hereditarnog) angioedema</article-title>
<trans-title-group xml:lang="en">
<trans-title>Mimics of hereditary angioedema</trans-title>
</trans-title-group>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Bare&#x0161;i&#x0107;</surname><given-names>Marko</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5884-1190</contrib-id><name><surname>Karanovi&#x0107;</surname><given-names>Boris</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Smiljani&#x0107; Tomi&#x010D;evi&#x0107;</surname><given-names>Ljiljana</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ani&#x0107;</surname><given-names>Branimir</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<aff id="aff1"><label>1</label>Zavod za klini&#x010D;ku imunologiju i reumatologiju, Klinika za unutarnje bolesti Medicinskog fakulteta Sveu&#x010D;ili&#x0161;ta u Zagrebu, Klini&#x010D;ki bolni&#x010D;ki centar Zagreb</aff>
</contrib-group>
<author-notes>
<corresp id="cor1">Adresa za dopisivanje: Boris Karanovi&#x0107;, dr. med., <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-5884-1190">https://orcid.org/0000-0002-5884-1190</ext-link> Zavod za klini&#x010D;ku imunologiju i reumatologiju, Klinika za unutarnje bolesti Medicinskog fakulteta, KBC Zagreb, Ki&#x0161;pati&#x0107;eva 12, 10000 Zagreb, e-po&#x0161;ta: <email xlink:href="boris.karanovic@gmail.com">boris.karanovic@gmail.com</email></corresp>
<fn fn-type="con">
<p content-type="fn-title">DOPRINOS AUTORA</p>
<p>K<sc>oncepcija</sc> <sc>ili</sc> <sc>nacrt</sc> <sc>rada</sc>: MB, BK, BA</p>
<p>P<sc>rikupljanje</sc>, <sc>analiza</sc> <sc>i</sc> <sc>interpretacija</sc> <sc>podataka</sc>: MB, BK, LJST</p>
<p>P<sc>isanje</sc> <sc>prve</sc> <sc>verzije</sc> <sc>rada</sc>: MB, BK</p>
<p>K<sc>riti&#x010D;ka</sc> <sc>revizija</sc>: MB, BK, LJST, BA</p>
</fn>
</author-notes>
<pub-date date-type="pub" publication-format="electronic"><month>02</month><year>2024</year></pub-date>
<pub-date date-type="pub" publication-format="print"><month>02</month><year>2024</year></pub-date>
<volume>146</volume>
<issue>1-2</issue>
<fpage>35</fpage>
<lpage>38</lpage>
<permissions>
<copyright-statement>Croatian Medical Association</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Croatian Medical Association</copyright-holder>
<license xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" specific-use="CC BY-NC-ND 4.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.</license-p></license>
</permissions>
<abstract>
<title>SA&#x017D;ETAK</title>
<p>Nasljedni (hereditarni) angioedem je bolest karakterizirana periodi&#x010D;nim, nepredvidivim oticanjima mekih tkiva razli&#x010D;itih lokalizacija i intenziteta s naj&#x010D;e&#x0161;&#x0107;e samoograni&#x010D;avaju&#x0107;im tijekom trajanja, te je u pravilu posredovan bradikininom. Bolest mo&#x017E;e uzrokovati blagi, estetski ili funkcionalni poreme&#x0107;aj, ali mo&#x017E;e dovesti i do smrtnog ishoda u slu&#x010D;aju zahva&#x0107;anja gornjih di&#x0161;nih putova i gu&#x0161;enja. Postoje stanja koja opona&#x0161;aju klini&#x010D;ku sliku hereditarnog angioedema, a mogu biti posredovana razli&#x010D;itim molekulama (bradikininom, histaminom i sl.), odnosno uzrokovana drugim mehanizmima nastanka. Cilj je ovog &#x010D;lanka na temelju ilustrativnih primjera upozoriti na naj&#x010D;e&#x0161;&#x0107;e opona&#x0161;atelje klini&#x010D;ke slike hereditarnog angioedema s kojima se susre&#x0107;u lije&#x010D;nici razli&#x010D;itih specijalnosti, posebice u radu u hitnoj slu&#x017E;bi.</p>
</abstract>
<trans-abstract xml:lang="en">
<title>SUMMARY</title>
<p>Hereditary angioedema is a disease characterized by periodic, unpredictable soft tissue swellings of different localization and intensity, is usually self-limiting and in most cases mediated by bradykinin. The disease can cause only a mild esthetic or functional disorder, but can also lead to death in case of upper respiratory tract affection and asphyxia. There are several states that resemble hereditary angioedema, that can be mediated by different molecules (bradykinin, histamine) or different pathophysiological mechanisms. The aim of the article is to address the most frequent mimics of hereditary angioedema that might be encountered in different medical specialties, especially in the emergency department, through illustrative examples from clinical practice.</p>
</trans-abstract>
<kwd-group kwd-group-type="author"><kwd>Deskriptori NASLJEDNI ANGIOEDEM &#x2013; dijagnoza, etiologija, farmakoterapija</kwd><kwd>ANGIOEDEM &#x2013; dijagnoza, etiologija, imunologija</kwd><kwd>INHIBITOR C1 ESTERAZE &#x2013; genetika, terapijska uporaba</kwd><kwd>BRADIKININ &#x2013; metabolizam</kwd><kwd>ACE INHIBITORI &#x2013; nuspojave</kwd><kwd>IMUNOGLOBULIN E &#x2013; imunologija</kwd></kwd-group>
<kwd-group kwd-group-type="translator" xml:lang="en"><title>Descriptors </title><kwd>ANGIOEDEMAS, HEREDITARY &#x2013; diagnosis, etiology, drug therapy</kwd><kwd>ANDGIOEDEMA &#x2013; etiology, drug therapy, immunology</kwd><kwd>COMPLEMENT C1 INHIBITOR PROTEIN &#x2013; genetics, therapeutic use</kwd><kwd>BRADYKININ &#x2013; metabolism</kwd><kwd>ANGIOTENSIN-CONVERTING ENZYME INHIBITORS &#x2013; adverse effects</kwd><kwd>IMMUNOGLOBULIN E &#x2013; immunology</kwd></kwd-group>
</article-meta>
</front>
<body>
<p>Angioedem nastaje kao posljedica poja&#x010D;ane permeabilnosti krvnih &#x017E;ila s posljedi&#x010D;nim izlaskom teku&#x0107;ine u podru&#x010D;je dubokog dermisa i potko&#x017E;nog tkiva. Karakteriziran je oteklinom razli&#x010D;ite veli&#x010D;ine i lokalizacije, a mo&#x017E;e biti posredovan razli&#x010D;itim mehanizmima nastanka. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>, <xref ref-type="bibr" rid="r2"><italic>2</italic></xref>) Urtika je ko&#x017E;na promjena s centralnim oticanjem povr&#x0161;inskog dijela ko&#x017E;e s okolnim eritemom razli&#x010D;itih veli&#x010D;ina i intenziteta koja je obi&#x010D;no popra&#x0107;ena svrbe&#x017E;om. (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>)</p>
<p>Nasljedni (hereditarni) angioedem (HAE) je bolest koja se naslje&#x0111;uje autosomno dominantno te se vrlo &#x010D;esto susre&#x0107;e kod nekoliko &#x010D;lanova iste obitelji. Oko 20% pacijenata ima <italic>de novo</italic> mutaciju pa izostanak simptoma kod &#x010D;lanova obitelji ne isklju&#x010D;uje postojanje bolesti. Hereditarni angioedem uzrokovan je deficitom inhibitora esteraze C1 (tip 1) ili naru&#x0161;enom funkcijom istog enzima (tip 2), &#x0161;to za posljedicu ima osloba&#x0111;anje vazoaktivnog amina bradikinina. Oba oblika bolesti uzrokovana su mutacijom gena SERPING1 na kromosomu 11 koji kodira inhibitor esteraze C1. (<xref ref-type="bibr" rid="r4"><italic>4</italic></xref>, <xref ref-type="bibr" rid="r5"><italic>5</italic></xref>) HAE s urednom razinom esteraze inhibitora C1 (prethodno zvan HAE tip 3) uzrokovan je mutacijama u za sada &#x0161;est identificiranih gena. Prezentiraju&#x0107;i simptomi ne razlikuju se od onih kod tipa 1 i 2, &#x0161;to predstavlja dijagnosti&#x010D;ki problem s obzirom na urednu razinu i funkciju esteraze inhibitora C1. (<xref ref-type="bibr" rid="r6"><italic>6</italic></xref>) Klini&#x010D;ka slika svih oblika HAE-a uklju&#x010D;uje pojavu oteklina &#x2013; angioedema na razli&#x010D;itim dijelovima tijela (licu, trupu, ekstremitetima, genitalnoj regiji). Tako&#x0111;er mogu biti zahva&#x0107;eni unutarnji organi (crijeva) te larinks, &#x0161;to predstavlja najproblemati&#x010D;nije o&#x010D;itovanje bolesti. (<xref ref-type="bibr" rid="r7"><italic>7</italic></xref>) Pojava urtika nije karakteristi&#x010D;na za HAE, a njihovo pojavljivanje prvenstveno upu&#x0107;uje na patolo&#x0161;ka stanja posredovana histaminom i imunoglobulinom E (IgE). (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>) Lije&#x010D;enje HAE-a ovisi o u&#x010D;estalosti i ozbiljnosti epizodnih napadaja angioedema. Lije&#x010D;enje uklju&#x010D;uje nadomjesnu primjenu inhibitora esteraze C1 (rekombinantnog [konestat-alfa] ili proizvedenog iz ljudske plazme), selektivni kompetitivni antagonist bradikininskog receptora tipa 2 (ikatibant), atenuirane androgene, traneksami&#x010D;nu kiselinu, inhibitore plazmatskog kalikreina (monoklonsko protutijelo lanadelumab i peroralni berotralstat). (<xref ref-type="bibr" rid="r8"><italic>8</italic></xref>&#x2013;<xref ref-type="bibr" rid="r10"><italic>10</italic></xref>) Brojni novi lijekovi i metode lije&#x010D;enja u razli&#x010D;itim su fazama istra&#x017E;ivanja. (<xref ref-type="bibr" rid="r11"><italic>11</italic></xref>)</p>
<sec sec-type="other1">
<title>Prikaz slu&#x010D;ajeva</title>
<p>Slu&#x010D;aj 1 (<xref ref-type="fig" rid="f1">Figure 1a</xref>): Mu&#x0161;karac u dobi od 69 godina pregledan je u hitnom otorinolaringolo&#x0161;kom prijmu zbog oteklina lica, usnica i vje&#x0111;a, a bez otekline jezika i bez otekline larinksa. Lije&#x010D;en je vi&#x0161;im dozama metilprednizolona i antihistaminika bez zna&#x010D;ajnijeg u&#x010D;inka. Zbog progresije oteklina intubiran je te potom hospitaliziran u jedinici intenzivnog lije&#x010D;enja. Primio je ikatibant te kasnije i dozu inhibitora esteraze C1 uz ostalu suportivnu terapiju. Postupno je do&#x0161;lo do smirivanja oteklina. Naknadno se saznaje da je lije&#x010D;io arterijsku hipertenziju inhibitorom enzima koji konvertira angiotenzin (engl. <italic>angiotension converting enzyme inhibitor</italic>, ACEI) lizinoprilom i hidroklorotiazidom. Uzrok angioedema: ACEI.</p>
<fig id="f1" position="float" fig-type="figure"><label>Figure 1</label><caption><p>Facial angioedema in three patients (a-c) and CT scan of a patient with superior vena cava syndrome (d)</p></caption><graphic xlink:href="LV-146-35-f1"></graphic></fig>
<p>Slu&#x010D;aj 2: &#x017D;ena u dobi od 33 godine javila se u hitni prijam zbog oteklina lica, usnica, ote&#x017E;anog disanja i promuklosti te pojave utrikarije i svrbe&#x017E;a. Ordinirana je terapija parenteralnim antihistaminikom i metilprednizolonom uz povoljan u&#x010D;inak. Tijekom opservacije do&#x0161;lo je do potpune regresije tegoba. Naknadno se saznaje da pacijentica jela odrezak od tune te vrlo brzo razvila angioedeme s urtikarijom. Uzrok angioedema: alergijska reakcija posredovana IgE-om.</p>
<p>Slu&#x010D;aj 3 (<xref ref-type="fig" rid="f1">Figure 1b</xref>): Mu&#x0161;karac u dobi od 62 godine javio se u hitni prijam zbog otekline jezika i lica. Lije&#x010D;en je metilprednizolonom i antihistaminikom bez zna&#x010D;ajnijeg u&#x010D;inka. Uz konestat-alfa oticanje se smanjilo. Uzimao je perindopril zbog arterijske hipertenzije. Uzrok angioedema: ACEI.</p>
<p>Slu&#x010D;aj 4 (<xref ref-type="fig" rid="f1">Figure 1c</xref>): Mu&#x0161;karac u dobi od 62 godine hospitaliziran je zbog asimetri&#x010D;nih oteklina lica i ote&#x017E;anog disanja. Metilprednizolon u visokim dozama i antihistaminici nisu bili u&#x010D;inkoviti, dok je ikatibant bio tek djelomi&#x010D;no u&#x010D;inkovit. Uz prekid perindoprila postupno dolazi do regresije oteklina. Tijekom hospitalizacije razvija simptome progresivne mi&#x0161;i&#x0107;ne slabosti te se nakon neurolo&#x0161;ke obrade utvrdi mijastenija gravis. Uzrok angioedema: ACEI.</p>
<p>Slu&#x010D;aj 5 (<xref ref-type="fig" rid="f1">Figure 1d</xref>): &#x017D;ena u dobi od 63 godine pregledana je u hitnoj ORL ambulanti zbog progresivnog oticanja lica, vrata i uvule. Od lijekova je uzimala ramipril u lije&#x010D;enju arterijske hipertenzije. S obzirom na klini&#x010D;ku sliku postavljena je sumnja na angioedem uzrokovan primjenom ACEI. No, s obzirom na to da je oticanje po&#x010D;elo prije vi&#x0161;e od mjesec dana i postupno progrediralo, zatra&#x017E;ena je daljnja obrada. Radiolo&#x0161;kom obradom utvr&#x0111;en je tumorski proces medijastinuma koji je svojom veli&#x010D;inom uzrokovao sindrom gornje &#x0161;uplje vene. Kasnijom bolni&#x010D;kom obradom dijagnosticira se diseminirani sitnostani&#x010D;ni neuroendokrini karcinom. Uzrok edema: sindrom gornje &#x0161;uplje vene.</p>
</sec>
<sec sec-type="other2">
<title>Rasprava</title>
<p>Klini&#x010D;ka slika angioedema u ve&#x0107;ini je slu&#x010D;ajeva vrlo sli&#x010D;na bez obzira na etiologiju, &#x0161;to stvara pote&#x0161;ko&#x0107;e i probleme prilikom dijagnosticiranja osnovne bolesti u pozadini tegoba. (<xref ref-type="bibr" rid="r7"><italic>7</italic></xref>) U svakodnevnoj rutinskoj praksi va&#x017E;no je razlikovati HAE od angioedema koji nastaju kao posljedica alergijske reakcije. (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>) Hereditarni angioedem i angioedem uzrokovan primjenom ACEI posredovani su bradikininom. (<xref ref-type="bibr" rid="r13"><italic>13</italic></xref>, <xref ref-type="bibr" rid="r14"><italic>14</italic></xref>) Alergijski angioedemi koji su znatno &#x010D;e&#x0161;&#x0107;i posredovani su prvenstveno histaminom i drugim vazoaktivnim aminima iz mastocita i/ili bazofila te imunoglobulinom E. Gotovo u pravilu uz ovakve alergijske reakcije posredovane IgE-om pojavljuju se i urtike te pruritus, &#x0161;to nije karakteristi&#x010D;no za HAE. (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>) Treba tako&#x0111;er razlikovati i ste&#x010D;ene angioedeme koji su mogu javiti uz limfoproliferativne i sustavne bolesti vezivnog tkiva. (<xref ref-type="bibr" rid="r12"><italic>12</italic></xref>) Rijetko se utvrde i razli&#x010D;ita stanja ili bolesti koja mogu uzrokovati otekline u podru&#x010D;ju lica i stazu krvi (kompresivni vaskularni sindromi), a koja nisu uzrokovana pove&#x0107;anom permeabilno&#x0161;&#x0107;u teku&#x0107;ine iz krvnih &#x017E;ila (angioedemom).</p>
<p>Angioedemi koji su posredovani bradikininom, a ne ubrajaju se u HAE, mogu biti uzrokovani &#x010D;esto kori&#x0161;tenim lijekovima za lije&#x010D;enje arterijske hipertenzije. Tako ACEI, osim svog povoljnog u&#x010D;inka na arterijsku hipertenziju, imaju za posljedicu i akumulaciju bradikinina. Bradikinin je potentni vazoaktivni amin-vazodilatator koji dovodi do pove&#x0107;ane permeabilnosti krvnih &#x017E;ila i klini&#x010D;ke slike oteklina mekih tkiva, tj. angioedema. ACEI su kontraindicirani u pacijenata kod kojih je dokazan HAE, s obzirom na to da mogu dovesti do &#x010D;e&#x0161;&#x0107;ih i ozbiljnijih epizoda oticanja. U slu&#x010D;aju epizode angioedema kod pacijenata koji uzimaju ACEI kao antihipertenziv svakako treba prekinuti lije&#x010D;enje i ACEI zamijeniti antihipertenzivom drugog mehanizma djelovanja. Angioedem uz ACEI mo&#x017E;e se pojaviti kod tek zapo&#x010D;etog, ali i kod dugotrajnog lije&#x010D;enja ACEI-jem. (<xref ref-type="bibr" rid="r13"><italic>13</italic></xref>, <xref ref-type="bibr" rid="r14"><italic>14</italic></xref>) &#x0160;to se ti&#x010D;e vrlo sli&#x010D;ne skupine antihipertenziva &#x2013; inhibitora receptora angiotenzina II (engl. <italic>angiotensin II receptor blockers</italic>, ARB) postoje razli&#x010D;iti podatci u literaturi. Prema nekim autorima kontraindicirani su u pacijenata s HAE-om i u onih s epizodama angioedema uz ACEI, dok ih dio autora preporu&#x010D;a kao zamjenu za ACEI u pacijenata kod kojih su se pojavio angioedem. (<xref ref-type="bibr" rid="r15"><italic>15</italic></xref>) Od ostalih lijekova koji bi se trebali izbjegavati u pacijenata s angioedemom lijekovi su koji sadr&#x017E;e estrogen, inhibitori mTOR-a (engl. <italic>mammalian target of rapamycin)</italic> (sirolimus i everolimus), inhibitori enkefalinaze, vrlo aktualni inhibitori dipeptidil peptidaze 4 i sli&#x010D;no. Kona&#x010D;no, treba imati na umu i polipragmaziju u primjeni lijekova koja mo&#x017E;e dovesti do razvoja ne&#x017E;eljenih interakcija u vidu angioedema. (<xref ref-type="bibr" rid="r14"><italic>14</italic></xref>) Dijelu angioedema ne mo&#x017E;e se odrediti jasan uzrok pa se nazivaju idiopatskima. Klasifikacija angioedema prikazana je shematski na <xref ref-type="fig" rid="f2">Figure 2</xref>.</p>
<fig id="f2" position="float" fig-type="figure"><label>Figure 2</label><caption><p>Classification of angioedema (modified according to reference <xref ref-type="bibr" rid="r2">2</xref>)</p></caption><graphic xlink:href="LV-146-35-f2"></graphic></fig>
<p>Pacijenti s angioedemom nerijetko se mogu susresti u ordinacijama lije&#x010D;nika obiteljske medicine, a kod izrazitih oticanja mekih tkiva (naj&#x010D;e&#x0161;&#x0107;e jezika) u hitnim prijamima medicinskih ustanova. To pogotovo vrijedi za pacijente s angioedemima uzrokovanima ACEI-jem, uzimaju&#x0107;i u obzir &#x0161;iroku primjenu ACEI-ja u u&#x010D;estaloj bolesti kao &#x0161;to je arterijska hipertenzija. Prema odre&#x0111;enim istra&#x017E;ivanjima u&#x010D;estalost nuspojave suhog ka&#x0161;lja iznosi 5 &#x2013; 35%, dok nuspojave angioedema izme&#x0111;u 0,5% i 0,10 &#x2013; 0,12% lije&#x010D;enih pacijenata. (<xref ref-type="bibr" rid="r16"><italic>16</italic></xref>, <xref ref-type="bibr" rid="r17"><italic>17</italic></xref>)</p>
<p>Svi pacijenti prikazani u ovom tekstu inicijalno su pregledani u hitnoj slu&#x017E;bi bolnice i zahtijevali su hitnu obradu i lije&#x010D;enje. Pacijenti koji imaju potvr&#x0111;enu dijagnozu HAE-a, a koji se javljaju u hitnu slu&#x017E;bu s epizodom angioedema, zahtijevaju promptnu primjenu lijeka za lije&#x010D;enje HAE-a i ne bi trebali biti dijagnosti&#x010D;ki i terapijski problem. Oni pacijenti koji imaju kompromitiran di&#x0161;ni put svakako trebaju hitnu primjenu lijekova s ciljem zaustavljanja gu&#x0161;enja. &#x0160;to ranija primjena terapije omogu&#x0107;uje br&#x017E;e zaustavljanje oticanja mekih tkiva. Problemati&#x010D;ni pacijenti su oni koji jo&#x0161; nemaju to&#x010D;nu etiolo&#x0161;ku dijagnozu angioedema (tj. dokazan uzrok angioedema), a prezentiraju se oteklinama u hitnoj slu&#x017E;bi. Takve pacijente treba &#x0161;to prije obraditi te ustanoviti postoji li zahva&#x0107;anje di&#x0161;nih struktura i/ili jezika. Inicijalna primjena glukokortikoida i antihistaminika preporu&#x010D;ljiva je s obzirom na to da je ve&#x0107;ina angioedema posredovana histaminom te bi trebala reagirati na primijenjenu terapiju. Prisutnost urtikarije samo potvr&#x0111;uje opravdanost primjene antihistaminika i glukokortikoida. Svakog pacijenta s angioedemom, bez obzira na uzrok, trebalo bi opservirati nakon primijenjene terapije bilo u ambulantnim bilo u bolni&#x010D;kim uvjetima do potpune stabilizacije op&#x0107;eg stanja. Nakon zbrinjavanja akutnog stanja i stabilizacije, pacijenta treba uputiti na obradu odgovaraju&#x0107;em specijalistu (klini&#x010D;kom farmakologu, dermatologu, alergologu ili klini&#x010D;kom imunologu).</p>
<p>Troje od pet pacijenata koristilo je ACEI za lije&#x010D;enje arterijske hipertenzije te je kod njih potvr&#x0111;en angioedem induciran ACEI-jem uz urednu koncentraciju i funkciju inhibitora esteraze C1. Time je isklju&#x010D;en HAE tip 1 i 2. Preporu&#x010D;en im je antihipertenziv drugog mehanizma djelovanja. Pacijentica s angioedemom i urtikarijom imala je tipi&#x010D;nu klini&#x010D;ku sliku alergijske reakcije posredovane IgE-om uz dobar u&#x010D;inak glukokortikoida i antihistaminika, stoga daljnja obrada u smjeru HAE-a nije bila indicirana. Klini&#x010D;ka slika pacijentice s agresivnim karcinomom medijastinuma opona&#x0161;ala je klini&#x010D;ku sliku HAE-a, no zapravo je bila rije&#x010D; o sindromu gornje &#x0161;uplje vene.</p>
</sec>
<sec sec-type="other3">
<title>Zaklju&#x010D;ak</title>
<p>Uzroci klini&#x010D;ke slike angioedema mogu biti raznovrsni, prvenstveno su posredovani IgE-om i histaminom te u manjoj mjeri bradikininom i drugim uzrocima. Pacijenti s angioedemom relativno se &#x010D;esto javljaju u hitne slu&#x017E;be medicinskih ustanova. Me&#x0111;u njima treba prepoznati pacijente s hereditarnim angioedemom i epizodnim oticanjima u sklopu njihove osnovne bolesti te ih lije&#x010D;iti u skladu s time. Pojava urtika uz angioedem nije karakteristi&#x010D;na za HAE te govori u prilog alergijske reakcije posredovane IgE-om. Odre&#x0111;eni broj pacijenata mo&#x017E;e imati angioedem kao nuspojavu ACEI-ja te se svakako naglasak stavlja na dobro uzimanje anamnesti&#x010D;kih podataka o prethodnim osobnim i obiteljskim bolestima, uzimanju lijekova (novouvedenih ili onih koje kroni&#x010D;no uzima) i medicinskih preparata, trajanju simptoma, izlo&#x017E;enosti razli&#x010D;itim okida&#x010D;ima bolesti i sli&#x010D;no. Otkrivanje uzroka angioedema bitno je radi primjene odgovaraju&#x0107;e terapije u akutnom napadaju (&#x010D;esto u hitnoj slu&#x017E;bi), modifikacije kroni&#x010D;ne medikamentozne terapije i upu&#x0107;ivanja pacijenta odgovaraju&#x0107;em specijalistu radi daljnjih pra&#x0107;enja. U slu&#x010D;aju da pacijent s angioedemom koristi ACEI, taj lijek treba zamijeniti lijekom drugog mehanizma djelovanja.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<p content-type="fn-title">INFORMACIJE O SUKOBU INTERESA</p>
<p>Autori nisu deklarirali sukob interesa relevantan za ovaj rad.</p>
</fn>
<fn fn-type="financial-disclosure">
<p content-type="fn-title">INFORMACIJA O FINANCIRANJU</p>
<p>Za ovaj &#x010D;lanak nisu primljena financijska sredstva.</p>
</fn>
</fn-group>
<ref-list>
<title>LITERATURA</title>
<ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciaccio</surname><given-names>CE</given-names></name></person-group>. <article-title>Angioedema: an overview and update.</article-title> <source>Mo Med</source>. <year>2011</year>;<volume>108</volume>(<issue>5</issue>):<fpage>354</fpage>&#x2013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">22073494</pub-id></mixed-citation></ref>
<ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giavina-Bianchi</surname><given-names>P</given-names></name><name><surname>Aun</surname><given-names>MV</given-names></name><name><surname>Motta</surname><given-names>AA</given-names></name><name><surname>Kalil</surname><given-names>J</given-names></name><name><surname>Castells</surname><given-names>M</given-names></name></person-group>. <article-title>Classification of angioedema by endotypes.</article-title> <source>Clin Exp Allergy</source>. <year>2015</year>;<volume>45</volume>(<issue>6</issue>):<fpage>1142</fpage>&#x2013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1111/cea.12551</pub-id><pub-id pub-id-type="pmid">25981351</pub-id></mixed-citation></ref>
<ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuberbier</surname><given-names>T</given-names></name><name><surname>Abdul Latiff</surname><given-names>AH</given-names></name><name><surname>Abuzakouk</surname><given-names>M</given-names></name><name><surname>Aquilina</surname><given-names>S</given-names></name><name><surname>Asero</surname><given-names>R</given-names></name><name><surname>Baker</surname><given-names>D</given-names></name><etal/></person-group> <article-title>The international EAACI/GA<sup>2</sup>LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria.</article-title> <source>Allergy</source>. <year>2022</year>;<volume>77</volume>(<issue>3</issue>):<fpage>734</fpage>&#x2013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1111/all.15090</pub-id><pub-id pub-id-type="pmid">34536239</pub-id></mixed-citation></ref>
<ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markovi&#x0107;</surname><given-names>AS</given-names></name><name><surname>Rozmani&#x0107;</surname><given-names>V</given-names></name><name><surname>Ani&#x0107;</surname><given-names>B</given-names></name><name><surname>Aberle</surname><given-names>N</given-names></name><name><surname>Raci&#x0107;</surname><given-names>G</given-names></name><name><surname>Novak</surname><given-names>S</given-names></name><etal/></person-group> <article-title>Smjernice za dijagnostiku i lije&#x010D;enje hereditarnog angioedema.</article-title> <source>Lijec Vjesn</source>. <year>2014</year>;<volume>136</volume>(<issue>5&#x2013;6</issue>):<fpage>117</fpage>&#x2013;<lpage>29</lpage>.<pub-id pub-id-type="pmid">25154179</pub-id></mixed-citation></ref>
<ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maurer</surname><given-names>M</given-names></name><name><surname>Magerl</surname><given-names>M</given-names></name><name><surname>Betschel</surname><given-names>S</given-names></name><name><surname>Aberer</surname><given-names>W</given-names></name><name><surname>Ansotegui</surname><given-names>IJ</given-names></name><name><surname>Ayg&#x00F6;ren-P&#x00FC;rs&#x00FC;n</surname><given-names>E</given-names></name><etal/></person-group> <article-title>The international WAO/EAACI guideline for the management of hereditary angioedema &#x2013; The 2021 revision and update.</article-title> <source>Allergy</source>. <year>2022</year>;<volume>77</volume>(<issue>7</issue>):<fpage>1961</fpage>&#x2013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1111/all.15214</pub-id><pub-id pub-id-type="pmid">35006617</pub-id></mixed-citation></ref>
<ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuraw</surname><given-names>BL</given-names></name></person-group>. <article-title>Hereditary angioedema with normal C1 inhibitor: Four types and counting.</article-title> <source>J Allergy Clin Immunol</source>. <year>2018</year>;<volume>141</volume>(<issue>3</issue>):<fpage>884</fpage>&#x2013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaci.2018.01.015</pub-id><pub-id pub-id-type="pmid">29410040</pub-id></mixed-citation></ref>
<ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosi-Schumacher</surname><given-names>M</given-names></name><name><surname>Shah</surname><given-names>SJ</given-names></name><name><surname>Craig</surname><given-names>T</given-names></name><name><surname>Goyal</surname><given-names>N</given-names></name></person-group>. <article-title>Clinical manifestations of hereditary angioedema and a systematic review of treatment options.</article-title> <source>Laryngoscope Investig Otolaryngol</source>. <year>2021</year>;<volume>6</volume>(<issue>3</issue>):<fpage>394</fpage>&#x2013;<lpage>403</lpage>. <pub-id pub-id-type="doi">10.1002/lio2.555</pub-id><pub-id pub-id-type="pmid">34195359</pub-id></mixed-citation></ref>
<ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caballero</surname><given-names>T</given-names></name></person-group>. <article-title>Treatment of Hereditary Angioedema.</article-title> <source>J Investig Allergol Clin Immunol</source>. <year>2021</year>;<volume>31</volume>(<issue>1</issue>):<fpage>1</fpage>&#x2013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.18176/jiaci.0653</pub-id><pub-id pub-id-type="pmid">33602658</pub-id></mixed-citation></ref>
<ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perkovi&#x0107;</surname><given-names>D</given-names></name><name><surname>Bare&#x0161;i&#x0107;</surname><given-names>M</given-names></name><name><surname>Ra&#x017E;ov Radas</surname><given-names>M</given-names></name><name><surname>Jurekovi&#x0107;</surname><given-names>I</given-names></name><name><surname>Novak</surname><given-names>S</given-names></name><name><surname>Ani&#x0107;</surname><given-names>B</given-names></name><etal/></person-group> <article-title>Dugoro&#x010D;na profilaksa hereditarnog angioedema.</article-title> <source>Lijec Vjesn</source>. <year>2022</year>;<volume>144</volume>:<fpage>411</fpage>&#x2013;<lpage>5</lpage>.</mixed-citation></ref>
<ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerji</surname><given-names>A</given-names></name><name><surname>Riedl</surname><given-names>MA</given-names></name><name><surname>Bernstein</surname><given-names>JA</given-names></name><name><surname>Cicardi</surname><given-names>M</given-names></name><name><surname>Longhurst</surname><given-names>HJ</given-names></name></person-group>. <article-title>Zuraw BL i sur; HELP Investigators. Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial.</article-title> <source>JAMA</source>. <year>2018</year>;<volume>320</volume>(<issue>20</issue>):<fpage>2108</fpage>&#x2013;<lpage>21</lpage>.  <comment>[Erratum in: JAMA. 2019 Apr 23;321] [16]</comment>:1636<pub-id pub-id-type="doi">10.1001/jama.2018.16773</pub-id><pub-id pub-id-type="pmid">30480729</pub-id></mixed-citation></ref>
<ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fijen</surname><given-names>LM</given-names></name><name><surname>Bork</surname><given-names>K</given-names></name><name><surname>Cohn</surname><given-names>DM</given-names></name></person-group>. <article-title>Current and Prospective Targets of Pharmacologic Treatment of Hereditary Angioedema Types 1 and 2.</article-title> <source>Clin Rev Allergy Immunol</source>. <year>2021</year>;<volume>61</volume>(<issue>1</issue>):<fpage>66</fpage>&#x2013;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1007/s12016-021-08832-x</pub-id><pub-id pub-id-type="pmid">33423210</pub-id></mixed-citation></ref>
<ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name></person-group>. <article-title>Where we are with acquired angioedema due to C1 inhibitor deficiency: A systematic literature review.</article-title> <source>Clin Immunol</source>. <year>2021</year>;<volume>230</volume>:<elocation-id>108819</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.clim.2021.108819</pub-id><pub-id pub-id-type="pmid">34358691</pub-id></mixed-citation></ref>
<ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smolinska</surname><given-names>S</given-names></name><name><surname>Antol&#x00ED;n-Am&#x00E9;rigo</surname><given-names>D</given-names></name><name><surname>Popescu</surname><given-names>FD</given-names></name></person-group>. <article-title>Bradykinin Metabolism and Drug-Induced Angioedema.</article-title> <source>Int J Mol Sci</source>. <year>2023</year>;<volume>24</volume>(<issue>14</issue>):<fpage>11649</fpage>. <pub-id pub-id-type="doi">10.3390/ijms241411649</pub-id><pub-id pub-id-type="pmid">37511409</pub-id></mixed-citation></ref>
<ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lochbaum</surname><given-names>R</given-names></name><name><surname>Hoffmann</surname><given-names>TK</given-names></name><name><surname>Greve</surname><given-names>J</given-names></name><name><surname>Hahn</surname><given-names>J</given-names></name></person-group>. <article-title>Concomitant medication in patients with bradykinin-mediated angioedema &#x2013; there&#x2019;s more than ACE inhibitors.</article-title> <source>J Dtsch Dermatol Ges</source>. <year>2023</year>;<volume>21</volume>(<issue>11</issue>):<fpage>1283</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/ddg.15154</pub-id></mixed-citation></ref>
<ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasmussen</surname><given-names>ER</given-names></name><name><surname>Potteg&#x00E5;rd</surname><given-names>A</given-names></name><name><surname>Bygum</surname><given-names>A</given-names></name><name><surname>von Buchwald</surname><given-names>C</given-names></name><name><surname>Hom&#x00F8;e</surname><given-names>P</given-names></name><name><surname>Hallas</surname><given-names>J</given-names></name></person-group>. <article-title>Angiotensin II receptor blockers are safe in patients with prior angioedema related to angiotensin-converting enzyme inhibitors &#x2013; a nationwide registry-based cohort study.</article-title> <source>J Intern Med</source>. <year>2019</year>;<volume>285</volume>(<issue>5</issue>):<fpage>553</fpage>&#x2013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1111/joim.12867</pub-id><pub-id pub-id-type="pmid">30618189</pub-id></mixed-citation></ref>
<ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bezalel</surname><given-names>S</given-names></name><name><surname>Mahlab-Guri</surname><given-names>K</given-names></name><name><surname>Asher</surname><given-names>I</given-names></name><name><surname>Werner</surname><given-names>B</given-names></name><name><surname>Sthoeger</surname><given-names>ZM</given-names></name></person-group>. <article-title>Angiotensin-converting enzyme inhibitor-induced angioedema.</article-title> <source>Am J Med</source>. <year>2015</year>;<volume>128</volume>(<issue>2</issue>):<fpage>120</fpage>&#x2013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.amjmed.2014.07.011</pub-id><pub-id pub-id-type="pmid">25058867</pub-id></mixed-citation></ref>
<ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerji</surname><given-names>A</given-names></name><name><surname>Blumenthal</surname><given-names>KG</given-names></name><name><surname>Lai</surname><given-names>KH</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name></person-group>. <article-title>Epidemiology of ACE Inhibitor Angioedema Utilizing a Large Electronic Health Record.</article-title> <source>J Allergy Clin Immunol Pract</source>. <year>2017</year>;<volume>5</volume>(<issue>3</issue>):<fpage>744</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaip.2017.02.018</pub-id><pub-id pub-id-type="pmid">28377081</pub-id></mixed-citation></ref>
</ref-list>
</back>
</article>
